A muscarinic acetylcholine receptor antagonist is a compound that competitively blocks one or more of the five muscarinic acetylcholine receptor (mAChR) subtypes, reducing the action of endogenous acetylcholine at G protein-coupled cholinergic synapses.[1] The class is defined by this shared pharmacological endpoint rather than by chemical structure, so its membership is chemically broad but functionally tight.
Members span naturally occurring tropane alkaloids carried by Atropa belladonna, Datura, Hyoscyamus niger, and Mandragora; the isolated alkaloid scopolamine; the synthetic antiparkinson agent trihexyphenidyl; and first-generation antihistamines such as diphenhydramine and promethazine whose anticholinergic activity is a secondary feature of their primary receptor profile. All converge on the same receptor population.
Therapeutically these compounds are used to dry secretions, reduce motion sickness, manage overactive bladder, ease Parkinsonian symptoms, and as sedating antihistamines.[2] Effects deepen with dose along a single axis of cholinergic blockade: dry mouth, blurred vision, and tachycardia at low exposures, progressing through confusion and disorientation, and at high supratherapeutic doses to an agitated delirium with hyperthermia, vivid hallucinations, and dense amnesia for the episode.[3]
Pharmacology
All members of this class bind the orthosteric acetylcholine-binding site on muscarinic receptors and prevent acetylcholine from activating them.[1] The five receptor subtypes (M1–M5) are unevenly distributed across tissues, and the clinical picture of class-wide blockade is the sum of subtype-specific blockades occurring simultaneously across multiple organ systems.[4]
| Receptor subtype | Principal distribution | Consequences of blockade |
|---|---|---|
| M1 | Cerebral cortex, hippocampus, striatum | Cognitive impairment, memory disruption, and at high exposure the delirium that defines toxicity[4] |
| M2 | Cardiac sinoatrial and atrioventricular nodes; presynaptic cholinergic terminals | Tachycardia from removal of vagal tone |
| M3 | Exocrine glands, smooth muscle, iris, ciliary body | Dry mouth, anhidrosis, mydriasis, cycloplegia, reduced GI motility, urinary retention |
| M4 | Striatum | Modulation of locomotor circuitry |
| M5 | Dopaminergic midbrain neurons | Implicated in reward circuitry; contribution to class effects is under active investigation[4] |
Crossing the blood–brain barrier is the pharmacokinetic variable that decides whether a class member produces central effects at all. Lipophilic tertiary amines — atropine, scopolamine, hyoscyamine, diphenhydramine, trihexyphenidyl — cross freely and disrupt cortical and hippocampal cholinergic circuitry; structurally quaternary antagonists remain largely peripheral and produce no delirium. Scopolamine crosses more readily than atropine at comparable doses, accounting for its greater CNS potency and pronounced amnestic profile.[3]
The convergent endpoint at high central exposure across every member is M1-driven disruption of cortical and hippocampal cholinergic tone, manifesting as the anticholinergic delirium syndrome. The receptor-subtype detail matters less for safety than this shared endpoint: any sufficiently CNS-penetrant mAChR antagonist can produce the toxidrome, and anticholinergic load is additive across members and across other drugs with secondary muscarinic activity.[2]
Substances
The class is illustrated by members from chemically unrelated families that share the same receptor target:
| Member | Subgroup | Role / distinctive feature |
|---|---|---|
| Atropa belladonna | Tropane alkaloid plant | Classical source of atropine and scopolamine; alkaloid load varies between specimens |
| Datura | Tropane alkaloid plant | Contains up to 28 belladonna alkaloids with ratios varying between and within species, making dose unpredictable from plant material[5] |
| Hyoscyamus niger | Tropane alkaloid plant | Carries hyoscyamine, scopolamine, and atropine; a historical European deliriant |
| Mandragora | Tropane alkaloid plant | Tropane-alkaloid-bearing plant of long-standing ritual and medicinal use |
| Scopolamine | Isolated tropane alkaloid | Among the highest CNS-to-peripheral potency ratios in the class; pronounced amnesia and sedation at supratherapeutic doses[3] |
| Trihexyphenidyl | Synthetic tertiary amine | Antiparkinson agent with documented misuse at supratherapeutic doses for euphoria and a delirious hallucinogenic state |
| Diphenhydramine | First-generation antihistamine | OTC availability drives the largest volume of anticholinergic overdose; cardiac sodium- and potassium-channel blockade at overdose adds QT prolongation and arrhythmia risk absent from the tropanes[6] |
| Promethazine | Phenothiazine antihistamine | Anticholinergic effect sits within a broader profile that also includes H1 and moderate D2 antagonism |
These members differ in potency, breadth of subtype coverage, and how readily they enter the brain, but each contributes anticholinergic load when combined with the others or with any drug carrying secondary muscarinic blockade.
Subjective Effects
Effects across the class track a single axis — deepening cholinergic blockade — and follow a steep dose-response gradient.[3]
| Exposure | Characteristic effects |
|---|---|
| Low / therapeutic | Dry mouth, dry eyes, blurred near vision, mild tachycardia, urinary hesitancy, reduced sweating, and either mild sedation or mild alerting depending on the member |
| Moderate supratherapeutic | Confusion, short-term memory impairment, disorientation, difficulty maintaining coherent speech, and the onset of agitation |
| High supratherapeutic | The full anticholinergic toxidrome — flushed dry skin, mydriasis with loss of accommodation, hyperthermia from anhidrosis, urinary retention, and an agitated delirium with vivid formed visual hallucinations the person interacts with as real; dense amnesia for the episode is the rule[7] |
Because the same axis of receptor blockade drives both the peripheral side effects seen at therapeutic doses and the central delirium that defines toxicity, the margin between heavy anticholinergic load and the toxidrome narrows quickly as more is added. The experience at high doses is overwhelmingly dysphoric rather than euphoric, and qualitatively distinct from classical psychedelic or dissociative states: it produces true hallucinations without insight, not perceptual distortions.[3]
Safety
Risk profile
The defining acute danger of this class is the anticholinergic toxidrome — hyperthermia from blocked sweating, tachycardia, and an agitated delirium that strips the person's ability to thermoregulate, communicate symptoms, or avoid self-injury. Severe presentations can include seizures, cardiac arrhythmia, coma, and death.
Hyperthermia is the most consistent life-threatening feature: M3 blockade of sweat glands abolishes evaporative cooling, and metabolic heat from agitation accumulates rather than dissipates.[7] Tachycardia from M2 blockade is universal across the class and tracks toxicity severity. Diphenhydramine carries an additional cardiac hazard absent from the tropane alkaloids: at overdose it blocks cardiac sodium and delayed-rectifier potassium channels, producing QT prolongation and risk of ventricular arrhythmia.[6]
With the tropane alkaloid plant sources, alkaloid load cannot be predicted in advance — content varies between and within species, so no reliable dose can be identified from plant material.[5] Severe presentations are documented from plant ingestion: a 22-year-old who ingested Datura stramonium progressed to coma, fever, and cardiac arrhythmia requiring mechanical ventilation, recovering only after supportive care and a cholinergic antidote.[8]
Anticholinergic burden is additive. Combining any two class members — or combining one with a drug carrying secondary muscarinic activity such as a tricyclic antidepressant, a first-generation antipsychotic, or an antimuscarinic bladder agent — can push total cholinergic blockade into the toxidrome range at doses that look individually modest.
Physostigmine, an acetylcholinesterase inhibitor that crosses the blood–brain barrier, reverses both central and peripheral toxicity by raising available acetylcholine and is the specific antidote in severe anticholinergic delirium; it is contraindicated when tricyclic co-ingestion is suspected, because cholinergic excess on top of tricyclic toxicity can precipitate bradycardia and seizures.[5]
Tolerance & dependence
Tolerance to the behavioural effects of mAChR antagonists develops with repeated dosing. Chronic administration of scopolamine and benztropine in animal models produces dose- and duration-dependent upregulation of muscarinic receptor density in the cerebral cortex and striatum — a "disuse supersensitivity" that parallels behavioural tolerance and primes the rebound seen on discontinuation.[9] Because all members act on the same receptor population, cross-tolerance within the class is expected from first principles.
Physical dependence is less prominent than with the CNS depressants, and withdrawal is not life-threatening in the way that alcohol or benzodiazepine withdrawal can be. Discontinuation after chronic exposure produces a rebound cholinergic syndrome — sweating, salivation, bradycardia, lacrimation, GI cramping — that mirrors the toxidrome in reverse and resolves as receptor density returns to baseline.
Abuse liability is uneven across the class: trihexyphenidyl has documented misuse patterns, diphenhydramine is misused particularly where other psychoactives are unavailable, and the predominantly dysphoric, amnestic character of plant-source experiences limits but does not eliminate intentional use.
Sustained anticholinergic exposure carries a distinct long-term concern. A meta-analysis of 26 observational studies (n = 621,548) reported that any anticholinergic use was associated with increased incidence of dementia, with long-term use (≥365 days) showing a stronger association; the authors note that a causal link cannot yet be inferred from observational data, but the consistency of the signal warrants clinical caution with prolonged use, particularly in older patients with reduced central cholinergic reserve.[10]
Recovery
Acute anticholinergic toxicity is reversible with prompt supportive care — cooling, sedation of agitation with benzodiazepines, cardiac monitoring — and in severe central cases with physostigmine under medical supervision. If you suspect anticholinergic poisoning in yourself or someone else, contact emergency services or a poison control centre; presentations driven by plant material can deteriorate quickly and benefit from early hospital management.For people who have been using a class member chronically and want to stop, a clinician can guide a measured reduction and manage the rebound cholinergic phase as receptor density returns to baseline.
Recovery resources, crisis lines, and support pathways → View all
Members
references
- [1] ^abCaulfield, M.P. and Birdsall, N.J.M. (1998) International Union of Pharmacology. XVII. Classification of Muscarinic Acetylcholine Receptors — Pharmacological Reviews PMID:9647869
- [2]
- [3] ^abcdeLakstygal AM, Kolesnikova TO, Khatsko SL, Zabegalov KN, Volgin AD, Demin KA, Shevyrin VA, Wappler-Guzzetta EA, Kalueff AV (2019) DARK Classics in Chemical Neuroscience: Atropine, Scopolamine, and Other Anticholinergic Deliriant Hallucinogens — ACS Chemical Neuroscience doi:10.1021/acschemneuro.8b00615
- [4] ^abcWess, J. and Eglen, R.M. and Gautam, D. (2007) Muscarinic acetylcholine receptors: mutant mice provide new insights for drug development — Nature Reviews Drug Discovery doi:10.1038/nrd2379
- [5] ^abcKrenzelok, E.P. (2010) Aspects of Datura poisoning and treatment — Clinical Toxicology doi:10.3109/15563651003630672
- [6]